POZ - ICAAC

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:
POZ Focus

Back to home » Newsfeed » Conference Coverage » ICAAC

Table of Contents

 
Diary of a Doc: Vaccine Update at ICAAC

ICAAC: Trizivir vs. Reyataz/Combivir

ICAAC: Norvir-Boosted Lexiva vs. Reyataz

Predictive Value of Viral Load Testing Questioned

ICAAC: MK-0518 Potent for Treatment Experienced

ICAAC: More Drug-Resistant HIV?

ICAAC: Prezista and Aptivus on Drug-Resistant HIV

Prezista Women's Study Opens for Enrollment

ICAAC Opens in San Francisco

ICAAC: Predicting Responses to Aptivus or Prezista

ICAAC: MK-0518 Appears Lipid Friendly

ICAAC: Abortion Pill for HIV? Questions Still Remain

 
What You're Talking About
It's Time for a TV Dramedy Series About Life With HIV (27 comments)

Let's Kick ASS - AIDS Survivor Syndrome (23 comments)

AHF Campaigns Against PrEP as a 'Public Health Intervention' (20 comments)

Depression, God and Staying Alive... (blog) (15 comments)

True Story - An essay by a gay journalist and author who is tired of living in fear of HIV (13 comments)

Health Care is a Human Right (8 comments)
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

ICAAC Opens in San Francisco



September 28, 2006—The 46th annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) opened yesterday in San Francisco with HIV and drug resistance among the hot topics so far. Over 12,000 doctors are in attendance, most of them from the U.S. (Check out our daily ICAAC coverage.)

 
Diary of a Doc: Vaccine Update at ICAAC
by Lloyd Bailey, MD
Developing a vaccine to prevent HIV infection has been a significant challenge, and, sadly, traditional vaccines are not expected to reach clinical use for another ten years.

ICAAC: Trizivir vs. Reyataz/Combivir
by Tim Horn
A new study suggests that 48 weeks of treatment with Trizivir® is comparable to a protease inhibitor-based regimen.

ICAAC: Norvir-Boosted Lexiva vs. Reyataz
by Tim Horn
Early data from a study comparing Lexiva (fosamprenavir) to Reyataz (atazanavir), both combined with low-dose Norvir (ritonavir), suggest that both drugs have similar effectiveness.


Predictive Value of Viral Load Testing Questioned
by Tim Horn
While the value of viral load testing is pretty much undisputed with respect to monitoring HIV-positive people while on treatment, a recent study by a nationwide team of HIV researchers strongly challenges conventional thinking about viral load as a measure of disease progression in those who aren't yet on therapy and questions the value of using viral load to determine when treatment should be started.


ICAAC: MK-0518 Potent for Treatment Experienced
by Tim Horn
New follow-up data from a clinical trial evaluating Merck's experimental integrase inhibitor MK-0518 in HIV-positive people who have tried and failed other HIV medications in the past indicates that the drug is effective in terms of reducing viral load for at least 24 weeks.


ICAAC: More Drug-Resistant HIV?
by Tim Horn
A growing number of HIV-positive people who have never taken HIV medications appear to have virus mutations that can cause drug resistance to available treatment options.

ICAAC: Prezista and Aptivus on Drug-Resistant HIV
by Tim Horn
Three reports presented Friday at the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco have shed additional light on the benefits of the protease inhibitors (PIs) Prezista (darunavir) and Aptivus (tipranavir) in the treatment of HIV-positive people who have tried and failed combination therapy in the past.

Prezista Women's Study Opens for Enrollment
by Tim Horn
Tibotec Therapeutics has announced the initiation of a clinical trial evaluating different responses to HIV treatment among women and men. The Gender, Race, and Clinical Experience (GRACE) study will be the largest clinical trial conducted to date to explore this important issue.

ICAAC Opens in San Francisco
The 46th annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) opened yesterday in San Francisco with HIV and drug resistance among the hot topics so far.

ICAAC: Predicting Responses to Aptivus or Prezista
by Tim Horn
For drug resistance testing to provide useful results, the companies that maintain the available assays frequently update the information that accompanies test results so that HIV-positive people and their healthcare providers can make important treatment decisions.


ICAAC: MK-0518 Appears Lipid Friendly
by Tim Horn
New data suggest that MK-0518 does not cause increased cholesterol or triglyceride as a side effect of treatment. The "late breaker" report, highlighting preliminary results from a study comparing Merck's experimental integrase inhibitor MK-0518 to Bristol-Myers Squibb's non-nucleoside reverse transcriptase inhibitor (NNRTI) Sustiva® (efavirenz), was presented on Wednesday at the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco.

ICAAC: Abortion Pill for HIV? Questions Still Remain
One of the most intriguing compounds to be studied as an HIV therapy is mifepristone, a controversial medication sold in the United States as Mifeprex® and used to chemically induce abortions in the early stages of pregnancy. While the scientific rationale behind using mifepristone as an anti-HIV agent has piqued the interest of researchers for several years, the results of a new clinical trial reported Wednesday at the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco indicate that its therapeutic potential for this indication remains unclear.



Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    adoniz89
    san dimas
    California


    Newhopenate
    New Hope
    Pennsylvania


    usuallyhappy
    Palm Springs
    California


    kmfdm221
    Arcata
    California
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Have you ever been tested for hepatitis C?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.